Amonafide Analog Metabolic Stability via Aryl Amine Relocation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Amonafide, an anti-cancer drug, undergoes metabolic instability due to NAT2-mediated acetylation, leading to variable efficacy and toxicity in patients, necessitating phenotyping or genotyping to optimize dosing, which delays treatment and increases costs.
Innovation Solution
Development of metabolically stable analogs with the aryl amine shifted from the 5- to the 6-position or completely lacking it, preventing NAT2 acetylation, while maintaining anti-cancer properties, such as compounds A1-A9, which are synthesized to retain biological activity and avoid metabolic inactivation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If amonafide is used as an anti-cancer drug, then anti-cancer efficacy is achieved, but metabolic instability occurs due to NAT2-mediated acetylation leading to variable efficacy and toxicity
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of amonafide, specifically shifting the aryl amine from the 5-position to the 6-position on the naphthalene ring. This structural parameter change prevents NAT2-mediated acetylation while preserving the compound's ability to intercalate DNA and inhibit topoisomerase II, thereby achieving metabolic stability without sacrificing anti-cancer efficacy
Solution Approach 2:
The invention extracts the problematic 5-position aryl amine group that is responsible for NAT2-mediated acetylation and metabolic instability. By removing this specific functional group or relocating it to the 6-position where it cannot be acetylated, the patent eliminates the source of metabolic variability while retaining the core anti-cancer activity of the molecule
2Object-affected harmful factors
If phenotyping or genotyping is performed to optimize amonafide dosing, then toxicity is reduced, but treatment time is delayed and costs increase
Solution Approach 1:
The patent replaces the complex and time-consuming phenotyping/genotyping process with a simple structural modification approach. The metabolically stable analogs are designed to inherently avoid NAT2-mediated metabolism, eliminating the need for patient-specific dosing adjustments based on acetylator status. This disposable solution (a single modified compound structure) replaces the ongoing need for diagnostic testing and dose optimization
Solution Approach 2:
The invention converts the harmful metabolic acetylation pathway into a beneficial feature by designing compounds that cannot be acetylated. The 6-position aryl amine structure, which would normally be a site for toxic acetylation, is positioned in a way that prevents NAT2 recognition and acetylation. This transforms the potential harm of metabolic activation into a benefit of metabolic stability, eliminating the need for phenotyping while maintaining efficacy
3Reliability
If aryl amine is present at the 5-position (as in amonafide), then anti-cancer activity is maintained, but NAT2 acetylation occurs causing metabolic instability
Solution Approach 1:
The patent applies inversion by reversing the position of the aryl amine group from the conventional 5-position to the 6-position on the naphthalene ring. This positional inversion changes the compound's interaction with NAT2 enzyme, preventing acetylation while preserving the molecule's ability to bind to DNA and inhibit topoisomerase II, thus maintaining anti-cancer activity without metabolic inactivation
Data Source
AI summary
The present invention relates to anti-cancer compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides analogs of the known anti-cancer compound amonafide, and structurally and functionally related compounds, and methods of using such compounds as therapeutic agents to treat a number of conditions associated with hyperproliferation.